App Helped Patients Stay in Medication-Assisted Treatment

The hardest part of medication-assisted treatment for opioid use disorder is often not starting it. It is staying on it. Dropout is where outcomes are lost, and it is the problem a category of FDA-authorized software was built to address.

One of these products, reSET-O, is authorized specifically as an adjunct to outpatient treatment that includes transmucosal buprenorphine. Its stated purpose is increasing retention.

A clinical trial funded by the National Institute on Drug Abuse found that patients who used it alongside buprenorphine and their usual clinical care had a significant reduction in treatment dropout compared with patients receiving standard care.

How Digital Therapy Supports Medication-Assisted Treatment

reSET-O delivers roughly 12 weeks of cognitive behavioral therapy through a smartphone, built on the community reinforcement approach, an evidence-based method that reinforces behavior change through structured incentives. It pairs with contingency management, where completing lessons and meeting treatment goals earns rewards.

The design logic is straightforward. Buprenorphine works when people keep taking it, and the weeks between clinic visits are when treatment quietly falls apart. Software can occupy that gap with structured therapeutic content rather than leaving it empty.

Broader app-based support works on the same principle from a more practical angle. Refill coordination, side effect logging between appointments, and reminders tied to extended-release injectable dosing schedules are administrative problems, and administrative problems are what causes a good treatment plan to lapse.

Why Retention Is the Measure That Matters

Retention is not a soft outcome in opioid use disorder. Staying on buprenorphine or methadone is associated with substantially lower overdose risk, and leaving treatment carries elevated risk precisely because tolerance falls while cravings often do not.

A tool that keeps someone in treatment longer is doing clinically meaningful work. This is why the indication language on these products is worth reading closely. reSET-O is meant to work with buprenorphine, not instead of it.

Its companion product, reSET, cleared in 2017 for substance use disorder, is indicated for patients in outpatient treatment who are not on opioid replacement therapy and whose primary substance is neither alcohol alone nor opioids.

Both passed to PursueCare after their original developer, Pear Therapeutics, filed for bankruptcy in 2023, and returned to service in 2024.

Understanding Buprenorphine

Buprenorphine is a partial opioid agonist. It occupies opioid receptors strongly enough to relieve withdrawal symptoms and reduce cravings, without producing the intensity of a full agonist like heroin or fentanyl.

That pharmacology is also what gives it a ceiling effect, which lowers overdose risk relative to full agonists. It is typically started after withdrawal symptoms have begun, and taken daily as a film or tablet dissolved in the mouth.

What Apps Cannot Do

The boundary is withdrawal management. Medical detox involves monitoring for symptoms that can escalate quickly, adjusting medication in response, and having a clinician available when things go wrong.

Alcohol and benzodiazepine withdrawal can produce seizures and can be fatal. Clinicians assess alcohol withdrawal severity with structured tools such as the CIWA-Ar and titrate medication accordingly.

No application performs that function, and none is cleared to attempt it. These products are authorized to support ongoing outpatient treatment, which is a different phase of care than getting through withdrawal safely.

Where the Evidence Is Thinner

The category deserves scrutiny alongside the enthusiasm. A 2025 perspective in npj Mental Health Research examined FDA-authorized software as a medical device in mental health and found that many devices cleared through the 510(k) pathway lacked direct evidence of effectiveness, relying instead on demonstrating equivalence to an earlier device.

The authors also identified authorized products whose pivotal trials had tested prototypes delivered on different platforms than the version eventually sold.

The practical takeaway is to ask which specific product has which specific evidence, rather than accepting the category wholesale. Chatbots, wearables tracking physiological stress markers, and geofencing alerts are all marketed for relapse support, and most are consumer wellness products rather than cleared medical devices.

Finding Medical Detox and Medication-Assisted Treatment

Never attempt alcohol or benzodiazepine detox without medical supervision. When evaluating a program, ask which substances it manages, what level of medical monitoring it provides overnight, whether it can start medication-assisted treatment during your stay rather than referring out afterward, and what the handoff to ongoing care looks like.

If a digital therapeutic interests you, it requires a prescription, so ask whether the program’s clinicians work with them. Detox.com’s directory lists accredited medical detox programs by location, substances treated, level of care, and insurance accepted. Call 800-996-6135(Sponsored) to learn more about your treatment options.